Tigermed Plans Privatization of Frontage and Divestment of Overseas Lab Services
News related to:Tigermed · 2 min read
HANGZHOU, China, Nov. 10, 2026 /CourierPR/ -- Hangzhou Tigermed Consulting Co., Ltd. (Stock Codes: 300347.SZ / 3347.HK) has announced its plans to participate in the privatization of its controlled subsidiary, Frontage Holdings Corporation (Stock Code: 1521.HK). Through its wholly-owned subsidiary, Hongkong Tigermed Co., Limited, Tigermed aims to integrate into the privatization process, alongside Charles River Laboratories International, Inc. (NYSE: CRL) and Dr. Song Li, Chairman of the Board of Frontage, and his trusts.
Tigermed also intends to divest Frontage's overseas laboratory services business, which includes preclinical research, laboratory testing, chemistry, and CMC services, to Charles River and Dr. Li. This divestment will allow Tigermed to retain Frontage's China business, focusing on its core clinical CRO (Contract Research Organization) business. The company believes that this strategic move will enable it to optimize its resource allocation, enhance operational efficiency, and strengthen its competitive edge in the China market.
According to Dr. Xiaoping Ye, Co-founder and Chairman of Tigermed, the privatization and subsequent asset restructuring represent a significant step in advancing the company's long-term development strategy.
The divestment of the overseas laboratory services business is expected to create value for Tigermed shareholders. The proceeds from this divestment will be used to further develop Tigermed's core clinical CRO business and enhance shareholder returns. Tigermed acquired a controlling stake in Frontage in 2014, and the privatization and subsequent asset restructuring are expected to generate significant gains for the company.
Tigermed, a leading global provider of integrated research and development solutions for the biopharmaceutical and medical device industries, currently represents a worldwide network of more than 180 locations with over 11,900 employees. The company is committed to moving its customers' development journey efficiently and cost-effectively, collaborating with over 4,200 customers.
Frontage Holdings Corporation, including Frontage Laboratories, is a US-based global CRO offering scientifically driven end-to-end integrated product development services from drug discovery through late-phase clinical trials and manufacturing. With over 25 years of experience, Frontage supports pharmaceutical and biotech companies with services including drug discovery, API synthesis, DMPK, safety and toxicology, formulation development, GMP manufacturing, analytical services, clinical trials, bioanalytical services, and central lab operations.
The proposed privatization and subsequent asset restructuring remain subject to the satisfaction of relevant conditions precedent and implementation requirements. For further details, interested parties should refer to the relevant announcements released by Tigermed and Frontage.